Contact Information: Contact: NanoLogix, Inc. Investor Relations Carol Surrena Telephone: 330-534-0800 E-mail:
NanoLogix Provides Operations Update and Notification of Shareholder Meeting
| Source: NanoLogix Incorporated
HUBBARD, OH--(Marketwire - July 28, 2009) - The company (PINKSHEETS : NNLX ), following
meetings in 2008 and 2009 with the US Environmental Protection Agency, has
developed a test kit utilizing BNP™ technology for the rapid testing of
water samples for specific strains of e-coli bacteria. The EPA is under a
Federal Court order mandating sub-24 hour testing results for multiple
microorganisms in beach waters by the year 2012.
During ongoing work on development of the water-quality testing kit for the
EPA, recent company research has indicated that NanoLogix's BNP™ and
BNC™ test kits may be used for detection and identification of viruses
when combined with antibody-coated magnetic particles. This is potentially
a major breakthrough for the company's diagnostic technology, adding
significantly to the battery of detection capabilities currently available
with BNP and BNC technology by moving beyond bacterial, spore and mold
detection to include the realm of viruses. NanoLogix plans to contract with
an Ohio-based research center with BSL-3 virology capabilities to perform
further research on the efficacy of this approach.
The company will ship 500 diagnostic test kits to an international public
health organization in Africa within the next week. This will be the first
use of NanoLogix technology in Africa.
NanoLogix recently filed a patent application for their BNF™
(BioNanoFilter) test kit technology. The BNF complements the company's
revolutionary BNP™ kit technology and provides the ability to work with
filterable material such as liquid-phase medical lab samples, water,
beverages, juices, etc. The BNF delivers similar time savings to the BNP
kits, yet enables the testing of large-volume samples.
NanoLogix is currently proceeding with national patent filings for BNP
technology in China, Japan, India, Brazil, the EU, and Russia. These
filings are the next step in pursuing from the initial PCT (Patent
Cooperation Treaty) filing done in 2007.
The company has retained the legal services of Arnold & Porter LLP (A&P),
an international law firm headquartered in Washington, DC and with
extensive experience working with biotech companies. A&P will be used to
advise the company on matters such as corporate governance, licensing, and
other issues related to future corporate direction.
Construction of the company's production cleanroom is projected to be
completed in late August, with equipment installation to follow.
September 18th has been set as the tentative date for the 2009 NanoLogix
shareholder meeting. Details of the meeting will follow in the near future.
About NanoLogix, Inc.
NanoLogix is a biotechnology company focused primarily on medical
diagnostics. Its products offer accelerated detection and identification of
microorganisms present in infectious and non-infectious human diseases,
such as tuberculosis, NTM, pneumonia, HIV/AIDS, cancer, cystic fibrosis,
anthrax, and plague. In addition to medical, Defense, and homeland security
applications, NanoLogix technology is applicable in pharmaceutical,
industrial, veterinary and environmental testing.
Patents granted to NanoLogix can be used in the areas of applied
microbiology, soil microbiology and bioremediation, microbial physiology,
molecular biology, pharmacology, pharmaco-kinetics, antibiotic sensitivity,
stem-cell research, and bioreactor-based hydrogen generation.
More information on NanoLogix is available at: www.nanologix.com
This press release contains statements, which may constitute
"forward-looking statements" within the meaning of the Securities Act of
1933 and the Securities Exchange Act of 1934, as amended by the Private
Securities Litigation Reform Act of 1995. Those statements include
statements regarding the intent, belief or current expectations of
NanoLogix, Inc., and members of its management as well as the assumptions
on which such statements are based. Prospective investors are cautioned
that any such forward-looking statements are not guarantees of future
performance and involve risks and uncertainties, and that actual results
may differ materially from those contemplated by such forward-looking
statements. The Company undertakes no obligation to update or revise
forward-looking statements to reflect changed assumptions, the occurrence
of unanticipated events or changes to future operating results.